Bristol-Myers Squibb Company, Johnson & Johnson Ink Hepatitis C Pact
Bristol-Myers Squibb Co. said Friday it will collaborate with a unit of Johnson & Johnson to study a potential combination therapy for chronic hepatitis C. The companies will study a regimen that combines Johnson & Johnson's drug TMC435 with Bristol-Myers Squibb's daclatasvir. The clinical trial of the drug cocktail will begin in the first half of 2012. It will include a combination of the two drugs, the drugs plus pegylated interferon and ribavirin, and the drugs plus ribavirin. Pegylated interferon and ribavirin have been staples of hepatitis C treatment for decades.